Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies, we are revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health. Through tireless efforts, breakthrough molecular science and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work – the patient.”
David D. Halbert
Chairman & CEO
Caris Life Sciences
Title: Caris Clinical Trial Spotlight: IDEAYA Biosciences: PKC inhibitor darovasertib (IDE196) effectively targets GNAQ/11 mutations in cancer
Description: Join Caris Pharmatech and Dr. Matthew Mauer, Vice President, Head of Medical Affairs and Clinical Oncology – IDEAYA Biosciences, for discussion on updated data results from IDE196.
Date: Wednesday, June 30, 2021
Time: 3:00 – 3:30pm
The Caris Molecular Minute is a podcast series led by Dr. Chadi Nabhan, Chairman of the Caris Precision Oncology Alliance™ who interviews many of today’s leading oncology experts and covers a variety of hot topics in precision oncology and advancing cancer care.
Caris Molecular Minute Podcast Library
Review and listen to each episode of the Caris Molecular Minute podcast series by clicking the button below.